David Mellman
Internal Medicine · Denver, CONPI 1972688554
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 649 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,644 and has fallen 56.7% since, to $1,144 in 2025. Among internal medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 649 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$1K
- AstraZeneca$1K
- Novo Nordisk$844
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$798
- Lilly USA, LLC$743
- plus $6K from 43 others
What the payments were for
- Food & beverage$11,75598%
- Education$1942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$11,949 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 160 | $154,191 |
| MounjaroTirzepatide | 82 | $90,905 |
| XareltoRivaroxaban | 58 | $62,037 |
| OzempicSemaglutide | 56 | $60,816 |
| MyrbetriqMirabegron | 45 | $48,690 |
| FarxigaDapagliflozin Propanediol | 50 | $41,043 |
| JardianceEmpagliflozin | 37 | $35,687 |
| BelsomraSuvorexant | 80 | $34,594 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $32,179 |
| Repatha SureclickEvolocumab | 29 | $28,062 |
| TrulicityDulaglutide | 25 | $25,304 |
| DayvigoLemborexant | 69 | $23,136 |
| LinzessLinaclotide | 15 | $20,552 |
| GemtesaVibegron | 25 | $16,788 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 79 | $9,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $445 | $162,098185 claims |
| Lilly USA, LLCMounjaro, Trulicity | $743 | $116,209107 claims |
| Johnson & JohnsonXarelto | $381 | $62,03758 claims |
| Novo NordiskOzempic | $844 | $60,81656 claims |
| Astellas Pharma US IncMyrbetriq | $502 | $48,69045 claims |
| AstraZenecaFarxiga | $1,121 | $41,04350 claims |
| GSKTrelegy Ellipta, Shingrix | $335 | $37,69958 claims |
| Boehringer IngelheimJardiance | $318 | $35,68737 claims |
| MerckBelsomra | $289 | $34,59480 claims |
| AbbVieLinzess, Synthroid | $1,421 | $26,55876 claims |
| Eisai Inc.Dayvigo | $253 | $23,13669 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $134 | $16,78825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Denver
- Kenneth OleszekDenver$60K
- Robert KeithDenver$49K
- Elena AnisimovaDenver$36K
- Chase BlackfordDenver$30K
- Matthew KoslowDenver$21K
- Katherine TsaiDenver$15K
- Saurabh MangalikDenver$14K
- Cara DawsonDenver$11K
- Jason HenryDenver$10K
- Emily AaronDenver$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.